Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, Nadine Tung, Henry T. Lynch, William D. Foulkes, Siranoush Manoukian, Peter Ainsworth, Susan L. Neuhausen, Rochelle Demsky, Andrea Eisen, Christian F. Singer, Howard Saal, Leigha Senter, Charis Eng, Jeffrey Weitzel, Pal Moller, Dawna M. Gilchrist, Olufunmilayo Olopade, Ophira GinsburgPing Sun, Tomasz Huzarski, Jan Lubinski, Steven A. Narod, David Euhus, Judy Garber, Gad Rennert, Kevin Sweet, Ruth Gershoni-Baruch, Christine Rappaport, Edmond Lemire, Lovise Maehle, Dominique Stoppa-Lyonnet, Mary Daly, Sofia Merajver, Ava Kwong, Louise Bordeleau, Carey A. Cullinane, Eitan Friedman, Wendy McKinnon, Marie Wood, Daniel Rayson, Wendy Meschino, Jane McLennan, Josephine Wagner Costalas, Robert E. Reilly, Tuya Pal, Susan Vadaparampil, Kenneth Offit, Mark Robson, Noah Kauff, Jan Klijn, Claudine Isaacs, Fergus Couch, Cezary Cybulski, Tomasz Byrski, Ania Jakubowska, Seema Panchal, Sonia Nanda, Aletta Poll, Kelly Metcalfe, Barry Rosen, Susan Randall Armel, Albert Chudley, Gareth Evans, Joanne Blum, Beth Karlan, Dana Zakalik, John Lunn, Talia Donenberg, Barbara Pasini, Raluca N. Kurz, Taya Fallen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.

Original languageEnglish
Pages (from-to)421-427
Number of pages7
JournalBreast Cancer Research and Treatment
Volume146
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Tamoxifen
Breast Neoplasms
Mutation
Odds Ratio
Chemoprevention
Risk Reduction Behavior
Case-Control Studies
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. / Gronwald, Jacek; Robidoux, Andre; Kim-Sing, Charmaine; Tung, Nadine; Lynch, Henry T.; Foulkes, William D.; Manoukian, Siranoush; Ainsworth, Peter; Neuhausen, Susan L.; Demsky, Rochelle; Eisen, Andrea; Singer, Christian F.; Saal, Howard; Senter, Leigha; Eng, Charis; Weitzel, Jeffrey; Moller, Pal; Gilchrist, Dawna M.; Olopade, Olufunmilayo; Ginsburg, Ophira; Sun, Ping; Huzarski, Tomasz; Lubinski, Jan; Narod, Steven A.; Euhus, David; Garber, Judy; Rennert, Gad; Sweet, Kevin; Gershoni-Baruch, Ruth; Rappaport, Christine; Lemire, Edmond; Maehle, Lovise; Stoppa-Lyonnet, Dominique; Daly, Mary; Merajver, Sofia; Kwong, Ava; Bordeleau, Louise; Cullinane, Carey A.; Friedman, Eitan; McKinnon, Wendy; Wood, Marie; Rayson, Daniel; Meschino, Wendy; McLennan, Jane; Costalas, Josephine Wagner; Reilly, Robert E.; Pal, Tuya; Vadaparampil, Susan; Offit, Kenneth; Robson, Mark; Kauff, Noah; Klijn, Jan; Isaacs, Claudine; Couch, Fergus; Cybulski, Cezary; Byrski, Tomasz; Jakubowska, Ania; Panchal, Seema; Nanda, Sonia; Poll, Aletta; Metcalfe, Kelly; Rosen, Barry; Armel, Susan Randall; Chudley, Albert; Evans, Gareth; Blum, Joanne; Karlan, Beth; Zakalik, Dana; Lunn, John; Donenberg, Talia; Pasini, Barbara; Kurz, Raluca N.; Fallen, Taya.

In: Breast Cancer Research and Treatment, Vol. 146, No. 2, 2014, p. 421-427.

Research output: Contribution to journalArticle

Gronwald, J, Robidoux, A, Kim-Sing, C, Tung, N, Lynch, HT, Foulkes, WD, Manoukian, S, Ainsworth, P, Neuhausen, SL, Demsky, R, Eisen, A, Singer, CF, Saal, H, Senter, L, Eng, C, Weitzel, J, Moller, P, Gilchrist, DM, Olopade, O, Ginsburg, O, Sun, P, Huzarski, T, Lubinski, J, Narod, SA, Euhus, D, Garber, J, Rennert, G, Sweet, K, Gershoni-Baruch, R, Rappaport, C, Lemire, E, Maehle, L, Stoppa-Lyonnet, D, Daly, M, Merajver, S, Kwong, A, Bordeleau, L, Cullinane, CA, Friedman, E, McKinnon, W, Wood, M, Rayson, D, Meschino, W, McLennan, J, Costalas, JW, Reilly, RE, Pal, T, Vadaparampil, S, Offit, K, Robson, M, Kauff, N, Klijn, J, Isaacs, C, Couch, F, Cybulski, C, Byrski, T, Jakubowska, A, Panchal, S, Nanda, S, Poll, A, Metcalfe, K, Rosen, B, Armel, SR, Chudley, A, Evans, G, Blum, J, Karlan, B, Zakalik, D, Lunn, J, Donenberg, T, Pasini, B, Kurz, RN & Fallen, T 2014, 'Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers', Breast Cancer Research and Treatment, vol. 146, no. 2, pp. 421-427. https://doi.org/10.1007/s10549-014-3026-3
Gronwald, Jacek ; Robidoux, Andre ; Kim-Sing, Charmaine ; Tung, Nadine ; Lynch, Henry T. ; Foulkes, William D. ; Manoukian, Siranoush ; Ainsworth, Peter ; Neuhausen, Susan L. ; Demsky, Rochelle ; Eisen, Andrea ; Singer, Christian F. ; Saal, Howard ; Senter, Leigha ; Eng, Charis ; Weitzel, Jeffrey ; Moller, Pal ; Gilchrist, Dawna M. ; Olopade, Olufunmilayo ; Ginsburg, Ophira ; Sun, Ping ; Huzarski, Tomasz ; Lubinski, Jan ; Narod, Steven A. ; Euhus, David ; Garber, Judy ; Rennert, Gad ; Sweet, Kevin ; Gershoni-Baruch, Ruth ; Rappaport, Christine ; Lemire, Edmond ; Maehle, Lovise ; Stoppa-Lyonnet, Dominique ; Daly, Mary ; Merajver, Sofia ; Kwong, Ava ; Bordeleau, Louise ; Cullinane, Carey A. ; Friedman, Eitan ; McKinnon, Wendy ; Wood, Marie ; Rayson, Daniel ; Meschino, Wendy ; McLennan, Jane ; Costalas, Josephine Wagner ; Reilly, Robert E. ; Pal, Tuya ; Vadaparampil, Susan ; Offit, Kenneth ; Robson, Mark ; Kauff, Noah ; Klijn, Jan ; Isaacs, Claudine ; Couch, Fergus ; Cybulski, Cezary ; Byrski, Tomasz ; Jakubowska, Ania ; Panchal, Seema ; Nanda, Sonia ; Poll, Aletta ; Metcalfe, Kelly ; Rosen, Barry ; Armel, Susan Randall ; Chudley, Albert ; Evans, Gareth ; Blum, Joanne ; Karlan, Beth ; Zakalik, Dana ; Lunn, John ; Donenberg, Talia ; Pasini, Barbara ; Kurz, Raluca N. ; Fallen, Taya. / Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. In: Breast Cancer Research and Treatment. 2014 ; Vol. 146, No. 2. pp. 421-427.
@article{bd0fbbd27c2e40c3afc72ceff3a86b4e,
title = "Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers",
abstract = "Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 {\%}. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 {\%}); of these 84 (25 {\%}) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 {\%} CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 {\%} CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 {\%} CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.",
author = "Jacek Gronwald and Andre Robidoux and Charmaine Kim-Sing and Nadine Tung and Lynch, {Henry T.} and Foulkes, {William D.} and Siranoush Manoukian and Peter Ainsworth and Neuhausen, {Susan L.} and Rochelle Demsky and Andrea Eisen and Singer, {Christian F.} and Howard Saal and Leigha Senter and Charis Eng and Jeffrey Weitzel and Pal Moller and Gilchrist, {Dawna M.} and Olufunmilayo Olopade and Ophira Ginsburg and Ping Sun and Tomasz Huzarski and Jan Lubinski and Narod, {Steven A.} and David Euhus and Judy Garber and Gad Rennert and Kevin Sweet and Ruth Gershoni-Baruch and Christine Rappaport and Edmond Lemire and Lovise Maehle and Dominique Stoppa-Lyonnet and Mary Daly and Sofia Merajver and Ava Kwong and Louise Bordeleau and Cullinane, {Carey A.} and Eitan Friedman and Wendy McKinnon and Marie Wood and Daniel Rayson and Wendy Meschino and Jane McLennan and Costalas, {Josephine Wagner} and Reilly, {Robert E.} and Tuya Pal and Susan Vadaparampil and Kenneth Offit and Mark Robson and Noah Kauff and Jan Klijn and Claudine Isaacs and Fergus Couch and Cezary Cybulski and Tomasz Byrski and Ania Jakubowska and Seema Panchal and Sonia Nanda and Aletta Poll and Kelly Metcalfe and Barry Rosen and Armel, {Susan Randall} and Albert Chudley and Gareth Evans and Joanne Blum and Beth Karlan and Dana Zakalik and John Lunn and Talia Donenberg and Barbara Pasini and Kurz, {Raluca N.} and Taya Fallen",
year = "2014",
doi = "10.1007/s10549-014-3026-3",
language = "English",
volume = "146",
pages = "421--427",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

AU - Gronwald, Jacek

AU - Robidoux, Andre

AU - Kim-Sing, Charmaine

AU - Tung, Nadine

AU - Lynch, Henry T.

AU - Foulkes, William D.

AU - Manoukian, Siranoush

AU - Ainsworth, Peter

AU - Neuhausen, Susan L.

AU - Demsky, Rochelle

AU - Eisen, Andrea

AU - Singer, Christian F.

AU - Saal, Howard

AU - Senter, Leigha

AU - Eng, Charis

AU - Weitzel, Jeffrey

AU - Moller, Pal

AU - Gilchrist, Dawna M.

AU - Olopade, Olufunmilayo

AU - Ginsburg, Ophira

AU - Sun, Ping

AU - Huzarski, Tomasz

AU - Lubinski, Jan

AU - Narod, Steven A.

AU - Euhus, David

AU - Garber, Judy

AU - Rennert, Gad

AU - Sweet, Kevin

AU - Gershoni-Baruch, Ruth

AU - Rappaport, Christine

AU - Lemire, Edmond

AU - Maehle, Lovise

AU - Stoppa-Lyonnet, Dominique

AU - Daly, Mary

AU - Merajver, Sofia

AU - Kwong, Ava

AU - Bordeleau, Louise

AU - Cullinane, Carey A.

AU - Friedman, Eitan

AU - McKinnon, Wendy

AU - Wood, Marie

AU - Rayson, Daniel

AU - Meschino, Wendy

AU - McLennan, Jane

AU - Costalas, Josephine Wagner

AU - Reilly, Robert E.

AU - Pal, Tuya

AU - Vadaparampil, Susan

AU - Offit, Kenneth

AU - Robson, Mark

AU - Kauff, Noah

AU - Klijn, Jan

AU - Isaacs, Claudine

AU - Couch, Fergus

AU - Cybulski, Cezary

AU - Byrski, Tomasz

AU - Jakubowska, Ania

AU - Panchal, Seema

AU - Nanda, Sonia

AU - Poll, Aletta

AU - Metcalfe, Kelly

AU - Rosen, Barry

AU - Armel, Susan Randall

AU - Chudley, Albert

AU - Evans, Gareth

AU - Blum, Joanne

AU - Karlan, Beth

AU - Zakalik, Dana

AU - Lunn, John

AU - Donenberg, Talia

AU - Pasini, Barbara

AU - Kurz, Raluca N.

AU - Fallen, Taya

PY - 2014

Y1 - 2014

N2 - Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.

AB - Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.

UR - http://www.scopus.com/inward/record.url?scp=84904129599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904129599&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3026-3

DO - 10.1007/s10549-014-3026-3

M3 - Article

C2 - 24951267

AN - SCOPUS:84904129599

VL - 146

SP - 421

EP - 427

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -